(Q42174618)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25842218%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

title

Opportunities and challenges in delivering influenza vaccine by microneedle patch (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25842218%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25842218%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

author name string

Erica Jacoby

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25842218%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

Harry F Hull

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25842218%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

Darin Zehrung

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25842218%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

language of work or name

English

0 references

publication date

1 April 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25842218%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25842218%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

volume

33

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25842218%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

issue

37

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25842218%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

page(s)

4699-4704

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25842218%20AND%20SRC:MED&resulttype=core&format=json

Estimation of potential global pandemic influenza mortality on the basis of vital registry data from the 1918-20 pandemic: a quantitative analysis.

4 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.062

Delivery of subunit influenza vaccine to skin with microneedles improves immunogenicity and long-lived protection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.062

Serological memory and long-term protection to novel H1N1 influenza virus after skin vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.062

Adjuvanted influenza vaccine administered intradermally elicits robust long-term immune responses that confer protection from lethal challenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.062

Microneedle vaccination with stabilized recombinant influenza virus hemagglutinin induces improved protective immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.062

Intradermal vaccination with influenza virus-like particles by using microneedles induces protection superior to that with intramuscular immunization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.062

Microneedle delivery of H5N1 influenza virus-like particles to the skin induces long-lasting B- and T-cell responses in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.062

Increased immunogenicity of avian influenza DNA vaccine delivered to the skin using a microneedle patch.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.062

Potent immunity to low doses of influenza vaccine by probabilistic guided micro-targeted skin delivery in a mouse model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.062

Rapid kinetics to peak serum antibodies is achieved following influenza vaccination by dry-coated densely packed microprojections to skin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.062

Dissolvable microneedle patches for the delivery of cell-culture-derived influenza vaccine antigens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.062

Transcutaneous immunization using a dissolving microneedle array protects against tetanus, diphtheria, malaria, and influenza.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.062

Long-term protective immunity from an influenza virus-like particle vaccine administered with a microneedle patch.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.062

Dose sparing intradermal trivalent influenza (2010/2011) vaccination overcomes reduced immunogenicity of the 2009 H1N1 strain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.062

Intradermally-administered influenza virus vaccine is safe and immunogenic in healthy adults 18-64 years of age.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.062

Comparison of the immunogenicity and safety of a split-virion, inactivated, trivalent influenza vaccine (Fluzone®) administered by intradermal and intramuscular route in healthy adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.062

Safety and efficacy of a novel microneedle device for dose sparing intradermal influenza vaccination in healthy adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.062

Evaluation of non-inferiority of intradermal versus adjuvanted seasonal influenza vaccine using two serological techniques: a randomised comparative study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.062

Intradermal influenza vaccine administered using a new microinjection system produces superior immunogenicity in elderly adults: a randomized controlled trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.062

Intradermal influenza vaccine for older adults: a randomized controlled multicenter phase III study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.062

Microneedles for drug and vaccine delivery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.062

Dissolving polymer microneedle patches for influenza vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.062

Fluzone(®) Intradermal vaccine: a promising new chance to increase the acceptability of influenza vaccination in adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.062

Acceptability of Intanza® 15 μg intradermal influenza vaccine in Belgium during the 2010-2011 influenza season

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.062

Perception and acceptance of intradermal influenza vaccination: Patient reported outcomes from phase 3 clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.062

Live attenuated influenza vaccine (FluMist®; Fluenz™): a review of its use in the prevention of seasonal influenza in children and adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.062

Safety and efficacy of live attenuated influenza vaccine in children 2-7 years of age.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.062

Cost-effectiveness of live attenuated influenza vaccine versus inactivated influenza vaccine among children aged 24-59 months in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.062

Cost benefit of influenza vaccination in healthy, working adults: an economic analysis based on the results of a clinical trial of trivalent live attenuated influenza virus vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.062

Effectiveness of live, attenuated intranasal influenza virus vaccine in healthy, working adults: a randomized controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.062

The safety and effectiveness of self-administration of intranasal live attenuated influenza vaccine in adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.062

A randomized control trial comparing immunogenicity, safety, and preference for self- versus nurse-administered intradermal influenza vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.062

Patient compliance in the use of Vivotif Berna(R) vaccine, typhoid vaccine, live oral Ty21a

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.062

10.1016/J.VACCINE.2015.03.062

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25842218%20AND%20SRC:MED&resulttype=core&format=json

release_mb3wjbd6rffg5kwyf4raut2ggu

4 March 2020

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/mb3wjbd6rffg5kwyf4raut2ggu

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25842218%20AND%20SRC:MED&resulttype=core&format=json